The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of participants in multiple myeloma trials since 2003. Asian Americans—who make up nearly 6 percent of … Continue reading “Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative”
Author: Liz Beatty
Liz Beatty is chief strategy officer at Inato, a clinical trials marketplace which flips the traditional model and allows sites to participate in the trials that are best aligned with their interests and that of their patients. She is focused on advancing Inato’s corporate strategy, developing partnerships and driving growth in North America. Previously, Liz headed digital clinical trials at Bristol-Myers Squibb, where she led digital innovation efforts across global clinical operations.